Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease

DSpace/Manakin Repository

Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease

Citable link to this page


Title: Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease
Author: Yu, Xiaocong; Li, Zihai; Zhou, Zhenxian; Kilby, J Michael; Jiang, Wei

Note: Order does not necessarily reflect citation order of authors.

Citation: Yu, Xiaocong, Zihai Li, Zhenxian Zhou, J Michael Kilby, and Wei Jiang. 2013. “Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease.” Epidemiology (Sunnyvale, Calif.) 3 (1): 120. doi:10.4172/2161-1165.1000120. http://dx.doi.org/10.4172/2161-1165.1000120.
Full Text & Related Files:
Abstract: Although T cells are the primary and most-studied targets of the Human Immunodeficiency Virus (HIV), B cells, especially memory B lymphocytes, are also chronically depleted in the course of HIV disease. Although the lack of CD4+ T cell help may explain these deficiencies, intrinsic defects in B lymphocytes appear to contribute to B cell depletion and reduced antibody (Ab) production in the setting of HIV, especially of some antigens eliciting T cell-independent responses. The gut mucosal barrier is disrupted in HIV disease, resulting in increased systemic exposure to microbial products such as Toll-Like Receptor (TLR) agonists. The association of enhanced systemic levels of TLR agonists and B cell dysfunction in HIV disease is not understood. This review discusses the potential role of microbial TLR agonists in the B cell depletion, enhanced autoantibody production and impaired responses to vaccination observed in HIV-infected hosts. Increased microbial translocation in HIV infection may drive B cells to produce autoantibodies and increase susceptibilities of B cells to apoptosis through activation-induced cell death. Determining the mechanisms of B cell perturbations in HIV disease will inform the design of novel strategies of improve immune responses to vaccines, reduce opportunistic infections and slow disease progression.
Published Version: doi:10.4172/2161-1165.1000120
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005894/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407026
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search